Mariner
TVTX icon

Mariner’s Travere Therapeutics TVTX Stock Holding History

Mariner’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Sell
10,847
-7,372
-40% -$220K ﹤0.01% 2804
2025
Q4 		$696K Buy
18,219
+9,359
+106% +$304K ﹤0.01% 2218
2025
Q3 		$212K Sell
8,860
-2,268
-20% -$42.6K ﹤0.01% 3125
2025
Q2 		$165K Sell
11,128
-636
-5% -$10.5K ﹤0.01% 3113
2025
Q1 		$211K Buy
11,764
+557
+5% +$11.3K ﹤0.01% 2958
2024
Q4 		$195K Buy
11,207
+111
+1% +$1.96K ﹤0.01% 3013
2024
Q3 		$155K Buy
+11,096
New +$116K ﹤0.01% 2997

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner's TVTX Position: Q1 2026 in Review

Mariner reduced its Travere Therapeutics (TVTX) stake by 40% in Q1 2026, selling an estimated $220K and leaving 10,847 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Mariner first reported a position in TVTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $696K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Mariner held 10,847 shares of Travere Therapeutics worth $322K as of Q1 2026.
  • Mariner sold 7,372 Travere Therapeutics shares in Q1 2026, an estimated $220K.
  • Travere Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2804 holding.
  • Mariner first reported a position in Travere Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Mariner's Travere Therapeutics position peaked at $696K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.